JP2003509369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003509369A5 JP2003509369A5 JP2001523001A JP2001523001A JP2003509369A5 JP 2003509369 A5 JP2003509369 A5 JP 2003509369A5 JP 2001523001 A JP2001523001 A JP 2001523001A JP 2001523001 A JP2001523001 A JP 2001523001A JP 2003509369 A5 JP2003509369 A5 JP 2003509369A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- group
- choh
- racemic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960004958 ketotifen Drugs 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 2
- 206010039705 Scleritis Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- -1 2,2,2-trichloroethoxycarbonyl Chemical group 0.000 description 1
- 206010057380 Allergic keratitis Diseases 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- IYSYPCSSDZBWHN-UHFFFAOYSA-N Nor-ketotifen Chemical compound C1=2C=CSC=2C(=O)CC2=CC=CC=C2C1=C1CCNCC1 IYSYPCSSDZBWHN-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15356699P | 1999-09-13 | 1999-09-13 | |
| US60/153,566 | 1999-09-13 | ||
| US19736300P | 2000-04-15 | 2000-04-15 | |
| US19798500P | 2000-04-15 | 2000-04-15 | |
| US19790600P | 2000-04-15 | 2000-04-15 | |
| US19790500P | 2000-04-15 | 2000-04-15 | |
| US60/197,906 | 2000-04-15 | ||
| US60/197,905 | 2000-04-15 | ||
| US60/197,363 | 2000-04-15 | ||
| US60/197,985 | 2000-04-15 | ||
| PCT/US2000/024892 WO2001019367A1 (en) | 1999-09-13 | 2000-09-12 | Optically active isomers of ketotifen and therapeutically active metabolites thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003509369A JP2003509369A (ja) | 2003-03-11 |
| JP2003509369A5 true JP2003509369A5 (https=) | 2007-09-27 |
| JP5116928B2 JP5116928B2 (ja) | 2013-01-09 |
Family
ID=27538454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001523001A Expired - Fee Related JP5116928B2 (ja) | 1999-09-13 | 2000-09-12 | ケトチフェン及びその治療上有効な代謝産物の光学活性異性体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7226934B1 (https=) |
| EP (1) | EP1218007B1 (https=) |
| JP (1) | JP5116928B2 (https=) |
| CN (1) | CN1391475A (https=) |
| AR (1) | AR034396A1 (https=) |
| AT (1) | ATE516804T1 (https=) |
| AU (1) | AU782816B2 (https=) |
| BR (1) | BR0013935A (https=) |
| CA (1) | CA2383222C (https=) |
| CY (1) | CY1112605T1 (https=) |
| DK (1) | DK1218007T3 (https=) |
| HU (1) | HUP0202671A3 (https=) |
| IL (2) | IL148368A0 (https=) |
| MX (1) | MXPA02002658A (https=) |
| MY (1) | MY134888A (https=) |
| PL (1) | PL353586A1 (https=) |
| PT (1) | PT1218007E (https=) |
| WO (1) | WO2001019367A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7226934B1 (en) * | 1999-09-13 | 2007-06-05 | Bridge Pharma, Inc. | Optically active isomers of ketotifen and therapeutically active metabolites thereof |
| US20100166804A1 (en) * | 2007-05-23 | 2010-07-01 | Dennis Penn | Methods |
| WO2009142772A2 (en) * | 2008-05-23 | 2009-11-26 | Mastcell Pharmaceuticals, Inc. | Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
| US9006210B2 (en) | 2008-06-13 | 2015-04-14 | Case Western Reserve University | Compositions and methods for treating corneal inflammation |
| WO2010047681A1 (en) * | 2008-10-24 | 2010-04-29 | Bridge Pharma, Inc. | Treating xerophthalmia with norketotifen |
| WO2010059894A1 (en) * | 2008-11-21 | 2010-05-27 | Bridge Pharma, Inc. | Ocular formulations of norketotifen |
| AU2010226249A1 (en) * | 2009-03-17 | 2011-10-13 | Aciex Therapeutics, Inc. | Ophthalmic formulations of ketotifen and methods of use |
| JP5978296B2 (ja) * | 2011-06-28 | 2016-08-24 | フジアン・ミンドン・レジュヴネイション・ファーマスーティカル・カンパニー・リミテッド | 抗アレルギ性ベンゾシクロヘプタチオフェン誘導体 |
| US8778971B2 (en) | 2012-10-23 | 2014-07-15 | Bridge Pharma, Inc. | Medicinal treatment of dermal diseases in companion animals |
| US8557846B1 (en) | 2012-10-23 | 2013-10-15 | Bridge Pharma, Inc. | Medicinal treatment of dermal diseases in dogs |
| US20150272941A1 (en) | 2012-10-30 | 2015-10-01 | Bridge Pharma, Inc. | Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen |
| US20140120121A1 (en) | 2012-10-30 | 2014-05-01 | Bridge Pharma, Inc. | Medicinal treatment of atopic inflammatory diseases |
| US9345697B2 (en) * | 2013-08-06 | 2016-05-24 | Bridge Pharma, Inc. | Methods of treatment of non-histaminic pruritus |
| US9439895B2 (en) | 2013-08-06 | 2016-09-13 | Bridge Pharma, Inc. | Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients |
| US9138431B2 (en) * | 2013-08-06 | 2015-09-22 | Bridge Pharma, Inc. | Methods of treatment of histamine H-4 receptor-related pruritus |
| CN104059056B (zh) * | 2014-06-26 | 2017-08-25 | 福建省闽东力捷迅药业有限公司 | 一种富马酸卢帕替芬晶型b及其制备方法 |
| CA2988564C (en) * | 2015-06-11 | 2021-10-05 | Bridge Pharma, Inc. | Methods of treatment of non-histaminic pruritus in mammals |
| US9694003B2 (en) | 2015-10-15 | 2017-07-04 | Bridge Pharma, Inc. | Formulations and methods for treating high intraocular pressure |
| CN106243096B (zh) * | 2016-07-29 | 2019-11-29 | 上海璃道医药科技有限公司 | 三环类药物的新用途 |
| WO2018048989A1 (en) | 2016-09-08 | 2018-03-15 | Emergo Therapeutics, Inc. | Mast cell stabilizers for treatment of hypercytokinemia and viral infection |
| EP3528809A4 (en) | 2016-10-18 | 2020-06-10 | Emergo Therapeutics, Inc. | Mast cell stabilizers for treatment of chronic inflammatory conditions |
| US10959992B2 (en) | 2019-02-22 | 2021-03-30 | Bridge Pharma Inc. | Methods of treatment of asthma and COPD |
| US20200268734A1 (en) * | 2019-02-22 | 2020-08-27 | Bridge Pharma, Inc. | Methods of treatment of respiratory disorders |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1089483A (en) | 1964-02-04 | 1967-11-01 | Sandoz Ltd | Improvements in or relating to 4h-benzo(4,5)cyclohepta (1,2-b) thiophene derivatives |
| FR1447527A (fr) | 1964-08-11 | 1966-07-29 | Sandoz Sa | Nouveaux benzo-cyclohepta-thiophènes et leur préparation |
| CH531000A (de) * | 1970-03-11 | 1972-11-30 | Sandoz Ag | Verfahren zur Herstellung neuer Benzocycloheptathiophene |
| BE794377A (fr) * | 1972-01-24 | 1973-07-23 | Sandoz Sa | Nouveaux derives du benzo-cyclohepta-thiophene |
| US3994974A (en) * | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| US4073915A (en) | 1975-05-20 | 1978-02-14 | Sandoz Ltd. | Treating asthma |
| US4128549A (en) | 1976-02-27 | 1978-12-05 | Sandoz Ltd. | Precursors of 4-(1-alkyl-4-piperidylidene-4H-benzo[4,5]cyclohepta-[1,2-b]thiophen-10(9H)-ones |
| CS263993B1 (cs) | 1988-03-11 | 1989-05-12 | Polivka Zdenek | Způsob přípravy čistých enantiomerů 4- (l-meíhyl-4-piperidyliden) -4,9-dihydrobenzo [ 4,5) cyklohepta [ 1,2-b ] - thiofen-lQ-onu |
| SG44477A1 (en) | 1988-04-28 | 1997-12-19 | Schering Corp | Fused polycyclic compounds compositions methods of manufacture and their use as paf antaginists anthihistamines and/or antiinflammatory agents |
| GB9012926D0 (en) * | 1990-06-09 | 1990-08-01 | Scras | Pyrrolo-pyridine derivatives |
| AU8854091A (en) * | 1990-10-10 | 1992-05-20 | Schering Corporation | Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use |
| DK0616524T3 (da) * | 1991-12-12 | 1999-06-21 | Glaxo Group Ltd | Lægemidler |
| ES2172510T3 (es) * | 1991-12-18 | 2002-10-01 | Astrazeneca Ab | Nueva combinacion de formoterol y budesonida. |
| US6040344A (en) * | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| WO1998043640A1 (en) | 1997-04-03 | 1998-10-08 | Bridge Pharma, Inc. | Benzocycloheptathiophene compounds |
| EP1014979A4 (en) * | 1997-06-09 | 2003-08-20 | Bridge Pharma Inc | CONNECTIONS WITH COMBINED ANTIHISTAMINIC AND FAST-CELL STABILIZING ACTIVITY FOR OPHTHALMOLOGICAL USE |
| US7226934B1 (en) * | 1999-09-13 | 2007-06-05 | Bridge Pharma, Inc. | Optically active isomers of ketotifen and therapeutically active metabolites thereof |
-
2000
- 2000-09-12 US US10/069,663 patent/US7226934B1/en not_active Expired - Fee Related
- 2000-09-12 PT PT00966709T patent/PT1218007E/pt unknown
- 2000-09-12 EP EP00966709A patent/EP1218007B1/en not_active Expired - Lifetime
- 2000-09-12 AT AT00966709T patent/ATE516804T1/de active
- 2000-09-12 HU HU0202671A patent/HUP0202671A3/hu unknown
- 2000-09-12 AU AU77014/00A patent/AU782816B2/en not_active Ceased
- 2000-09-12 IL IL14836800A patent/IL148368A0/xx active IP Right Grant
- 2000-09-12 JP JP2001523001A patent/JP5116928B2/ja not_active Expired - Fee Related
- 2000-09-12 DK DK00966709.8T patent/DK1218007T3/da active
- 2000-09-12 CN CN00815422A patent/CN1391475A/zh active Pending
- 2000-09-12 CA CA002383222A patent/CA2383222C/en not_active Expired - Fee Related
- 2000-09-12 MX MXPA02002658A patent/MXPA02002658A/es active IP Right Grant
- 2000-09-12 WO PCT/US2000/024892 patent/WO2001019367A1/en not_active Ceased
- 2000-09-12 PL PL00353586A patent/PL353586A1/xx not_active Application Discontinuation
- 2000-09-12 BR BR0013935-1A patent/BR0013935A/pt not_active Application Discontinuation
- 2000-09-13 AR ARP000104790A patent/AR034396A1/es not_active Application Discontinuation
- 2000-09-13 MY MYPI20004252A patent/MY134888A/en unknown
-
2002
- 2002-02-25 IL IL148368A patent/IL148368A/en not_active IP Right Cessation
-
2007
- 2007-04-30 US US11/796,998 patent/US7557128B2/en not_active Expired - Fee Related
-
2009
- 2009-02-12 US US12/378,231 patent/US7872025B2/en not_active Expired - Fee Related
-
2011
- 2011-10-17 CY CY20111100984T patent/CY1112605T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003509369A5 (https=) | ||
| TWI658836B (zh) | 治療肺部疾病的高穿透力前藥組合物、其醫藥組合物及其用途 | |
| JP5116928B2 (ja) | ケトチフェン及びその治療上有効な代謝産物の光学活性異性体 | |
| JP2011504490A5 (https=) | ||
| JP3861250B2 (ja) | ５−ｈｔ２拮抗剤による強迫性障害処置剤 | |
| US11654198B2 (en) | Application of combination of polyethylene glycol and local anesthetic in non-narcotic analgesia | |
| CN102892418A (zh) | 含烟碱的药物组合物 | |
| JP2002521468A5 (https=) | ||
| HUP0102706A2 (hu) | Hatóanyagok salétromsavval alkotott észterei és nitrátsói | |
| EP1123702A1 (en) | Analgesics | |
| JP2020073513A (ja) | α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法 | |
| JP2003513075A5 (https=) | ||
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors | |
| ES2296964T3 (es) | Compuestos a base de nitrato organico para el tratamiento de ateroesclerosis y enfermedades vasculares. | |
| JP2003529597A5 (https=) | ||
| JP2004514709A5 (https=) | ||
| JP2004509871A5 (https=) | ||
| US6197796B1 (en) | Anticancer composition comprising a diaminotrifluoromethylpyridine derivative | |
| RU2002109706A (ru) | Оптически активные изомеры кетотифена и их терапевтически активные метаболиты | |
| CA2290557C (en) | Use of 4-substituted tetrahydropyridines for making medicines acting on tgf-.beta.1 | |
| WO2004032964A1 (ja) | アレルギー性疾患治療剤 | |
| JP2004512376A5 (https=) | ||
| JP2002541190A (ja) | 気分障害治療用医薬を製造するためのオサネタントの使用 | |
| WO2010038240A9 (en) | Pharmaceutical composition comprising nimesulide and levocetirizine | |
| JP2004509869A5 (https=) |